Evotec is a leader in the discovery and development of novel small molecule drugs.

Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABA_A receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.

In research collaborations, Evotec has established itself as the partner of choice for Pharmaceutical and Biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.

Evotec’s contract research services and capabilities include the following:

FRAGMENT BASED DRUG DISCOVERY

• High Throughput Fragment Screening
• Fragment to Lead

ASSAY DEVELOPMENT & SCREENING

• Assay Development
• Medium Throughput Screening
• High Throughput Screening
• Screening Library
• High Content Screening
• Compound Profiling
• High Throughput Fragment Screening

COMPOUND LIBRARIES

• Library Design
• Library Synthesis
• Compound Management

MEDICINAL CHEMISTRY

• Structural Biology
• Target Class Expertise
• Hit to Lead & Lead Optimisation
• Computational Chemistry
• Pharmacokinetics
• Primary & Secondary Screening Support

CHEMICAL & PHARMACEUTICAL DEVELOPMENT

• Custom Preparation
• Process Research & Development
• Analytical Method Development & Testing
• Pre-Formulation Package
• State-of-the-art Pilot Plants (FDA and MHRA inspected; ISO14001 compliant)
• Drug Formulation & Manufacture (Class A, B and C clean room facilities)

To fully exploit the potential of its capabilities, Evotec looks to complement its traditional fee-for-service business with higher value, results-driven projects in core areas by sharing in the customer's risk and success through significant milestone payments and royalties.